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Abstract
Small-molecule probes can illuminate biological processes and aid in the assessment of emerging 
therapeutic targets by perturbing biological systems in a manner distinct from other experimental 
approaches. Despite the tremendous promise of chemical tools for investigating biology and 
disease, small-molecule probes were unavailable for most targets and pathways as recently as a 
decade ago. In 2005, the U.S. National Institutes of Health launched the decade-long Molecular 
Libraries Program with the intent of innovating in and broadening access to small-molecule 
science. This Perspective describes how novel small-molecule probes identified through the 
program are enabling the exploration of biological pathways and therapeutic hypotheses not 
otherwise testable. These experiences illustrate how small-molecule probes can help bridge the 
chasm between biological research and the development of medicines, but also highlight the need 
to innovate the science of therapeutic discovery.
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Introduction
Despite remarkable advances in chemistry and biology, small molecule drug discovery 
remains a slow, costly, and low-yielding activity. In fact, productivity in drug discovery has 
fallen in recent years. It is estimated that only about 1 in 10 drug candidates entering the 
clinic are eventually approved – despite increasing investment (Hay et al., 2014). A prime 
hurdle is our inability to predict the physiologic consequences of modulating candidate drug 
targets in humans. Currently, lack of sufficient efficacy is the cause of clinical candidates 
failing in about 50% of Phase-II trials (Arrowsmith, 2011a) and 66% of Phase-III trials 
(Arrowsmith, 2011b). This high rate of attrition results from an inadequate understanding of 
how diseases are caused and maintained in human populations.
Expectations regarding the therapeutic relevance of a target are often based on inferences 
from experiments that alter nucleic acids encoding the putative target (e.g., deleting a DNA 
sequence; degrading or overexpressing an RNA sequence). Yet most small-molecule drugs 
alter the functions of proteins, and the correlation between perturbing nucleic acids and their 
encoded proteins is imperfect. Modulating the functions of candidate drug targets with small 
molecules would provide insights with far greater relevance to drug discovery. However, the 
current absence of effective small-molecule probes or ‘tool compounds’ for the vast 
majority of proteins limits a systematic application of this approach to target validation.
Advances in understanding human biology, particularly ‘experiments of nature’ revealed 
with increasing frequency by human genetics, are now shining a light on many complex 
diseases and pointing to targets with a much higher likelihood of providing a therapeutic 
benefit safely than those derived from model systems (Plenge et al., 2013). And the 
increasing availability of patient-derived cells and advances in precise genome-editing 
methods are providing more effective model systems for investigating the functional impact 
of observed human genetic variation.
But these insights also create a demand for small-molecule probes. The therapeutic 
implications of these genetic alterations are intriguing, but not certain. Not only do they 
raise the ‘gene vs. protein’ issue above – they often reflect heritable modulations from birth 
so the effect of targeting an implicated protein by a therapeutic in an ongoing disease is 
uncertain. Also, the therapeutic strategies suggested by these studies frequently point to 
targets that are inaccessible to protein-based drugs and for which small-molecule modulators 
are currently nonexistent – targets that fall outside traditional drug classes and have been 
labeled 'undruggable' by some within the pharmaceutical and academic communities. There 
is an urgent need to innovate chemistry and chemical biology in ways that enable small-
molecule modulation of the challenging targets at the heart of disease.
In 2005, in an effort to bridge the chasm between basic biological research and the 
medicines that should in principle derive from insights into disease, the U.S. National 
Institutes of Health (NIH) initiated the decade-long Molecular Libraries Program (MLP) 
(Austin et al., 2004). At that time, small-molecule discovery techniques, including high-
throughput screening (HTS) and medicinal chemistry expertise, existed predominantly 
within pharmaceutical companies. Following a three-year pilot phase, the MLP launched the 
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Molecular Libraries Probe Production Centers Network (MLPCN), which comprised 
Comprehensive Screening Centers, Specialized Screening Centers and Specialized 
Chemistry Centers (Fig. 1). These centers were among the earliest efforts to bring systematic 
small-molecule screening into academic settings.
The MLP was designed as an experiment in integrating big science and individual 
investigator-led science. Individual investigators submitted funding applications to the NIH 
for assay development or screening projects. For screening projects that were selected 
through peer review, MLP Centers conducted high-throughput screens using an MLP small-
molecule library that grew over the course of the program to a final size of about 390,000 
compounds. Novel compounds emerging from the academic synthetic chemistry 
community, for instance small, chiral compounds having novel skeletons derived from 
diversity-oriented synthesis (DOS) and other compounds derived from the NIH-funded 
Chemical Methodologies and Library Development (CMLD) program, made up about 5% of 
the compound library and yielded small-molecule probes, including some highlighted 
below, that would not have been discovered otherwise. Following on the screens, the MLP 
pursued chemical optimization of hits with the aim of identifying small-molecule probes, 
including ones targeting proteins viewed as challenging, with sufficient potency and 
selectivity to provide ‘high-quality’ tool compounds (Frye, 2010; Oprea et al., 2009; 
Workman and Collins, 2010). These probes were envisioned as a first step towards the 
testing of novel biological and therapeutic hypotheses.
With the conclusion of the program, we can now look back at the progress achieved over the 
decade of the MLP and forward at how to benefit from the lessons learned. We summarize 
advances in discovering biologically active small molecules and illustrate how these 
advances are yielding a rich armamentarium of novel small-molecule probes and, perhaps 
most notably, experimental paths to therapeutics discovery. The series of 'vignettes' 
described here provide examples of methodological development and small-molecule probe 
discovery that is enabling the testing of specific therapeutic hypotheses. These examples 
highlight the importance of small-molecule probes as critical tools for accelerating 
translational research, but also emphasize the tremendous hurdles that remain to be cleared 
if we are to capitalize fully on the rapid pace of biological advances to improve human 
health. If the lack of productivity of therapeutics discovery is to be reversed, transformative 
innovation will be needed to push back barriers at every stage of small-molecule 
therapeutics discovery.
Bridging the chasm
The most visible output of the MLP is a set of 375 small-molecule probes for exploring 
biology. MLP probes cover a diverse spectrum of target classes, including well-investigated 
classes such as kinases and G protein-coupled receptors (GPCRs) and less frequently 
investigated classes such as GTPases, proteases and RNA-binding proteins (Fig. 2). This 
broad coverage of target space highlights the intentional focus of the MLP Network on 
relatively under-explored proteins. Many of these compounds were ‘first-in-class’ probes 
that provided initial evidence for the chemical tractability of a previously recalcitrant target 
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or that modulated a target by a distinct mechanism from previous small molecules 
(Supplementary Table 1).
Perhaps the most exciting outcome of the MLP was the impact of probe-discovery efforts in 
highlighting paths for therapeutics discovery. Here, we describe a number of vignettes that 
illustrate the breadth of the translational impact of small-molecule probes identified through 
MLP research. These vignettes highlight advances in small-molecule science, as well as 
insights gained through the use of small-molecule probes in diverse disease contexts. Many 
of these and other MLP projects have directly catalyzed efforts to translate emerging 
biomedical insights (Table 1).
Targeting poorly characterized enzymes
Small-molecule probes can aid efforts to annotate the function of poorly characterized 
enzymes, including those that human genetic studies have implicated in disease. However, it 
is difficult to establish a typical biochemical high-throughput screening assay to identify 
modulators of an enzyme if the substrate is not known. Activity-based protein profiling 
(ABPP) makes use of reactive small-molecule ligands to label covalently the active sites of 
members of large enzyme families, including those that are uncharacterized (Nomura et al., 
2010). In this approach, broadly reactive ABPP probes can be used in a competition 
experiment to identify small molecules that selectively reduce labeling of a desired enzyme 
target. Despite the potential, this substrate-free screening approach has not been widely used 
because the current competitive ABPP methods relies on SDS-PAGE or mass spectrometry 
assays and can only be used to evaluate, at most, a few hundred compounds.
The MLP undertook a project to develop a high-throughput fluorescence polarization 
technology for ABPP-based screening (fluopol-ABPP) (Bachovchin et al., 2009). A small 
fluorophore in solution rotates rapidly and emits a low fluorescence polarization signal, 
whereas a fluorophore bound to a protein rotates more slowly and emits a higher signal. 
Based on this known property, an ABPP assay was developed in which fluorescent ABPP 
probe labeling of an enzyme target generates a signal that is then reduced when a small 
molecule ‘hit’ effectively competes for binding. This approach proved generally applicable 
to high-throughput screening in multi-well format. For instance, screening 20,000 small 
molecules in 384-well plates led to the identification of multiple small molecules that 
blocked serine fluorophosphonate (FP)-rhodamine labeling of the serine hydrolase 
retinoblastoma-binding protein-9 (RBBP9), a cancer-associated enzyme. Secondary 
chemoproteomic assays in mouse brain fractions and human cell lysates subsequently 
identified the natural product emetine (ML081; Fig. 3) as the first RBBP9 inhibitor that is 
selective for this serine hydrolase family member (Bachovchin et al., 2009).
Small molecule inhibitors of protein phosphatase methylesterase-1 PME-1, a regulator of 
protein phosphatase 2A (PP2A) that has been linked to cancer and neurodegeneration, had 
not previously been identified, in part due to the challenges of designing an in vitro 
biochemical assay suitable for monitoring the carboxymethylation state of PP2A. A fluopol-
ABPP screen yielded initial hits, from which four novel aza-β-lactams were shown in 
follow-up assays to selectively inhibit PME-1 in human cells. The most potent inhibitor, 
ML174 (ABL127; Fig. 3), inhibited PME-1 with a low nanomolar IC50 and had no activity 
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against more than 50 other serine hydrolases. In mice, ML174 selectively inactivated PME-1 
and increased the levels of PP2A carboxymethylation in the brain (Bachovchin et al., 2011). 
Strikingly, the aza-β-lactam hits are examples of innovations resulting from diversity 
synthesis performed by an academic chemistry laboratory – such compounds are distinct 
from conventional screening compounds available from vendors. The aza-β-lactam scaffold 
has subsequently proven to be a versatile chemotype for developing selective serine 
hydrolase inhibitors (Zuhl et al., 2012).
The MLP has also developed a modified ABPP method that can be used to read out cellular 
and in vivo target engagement, an often-missing link in the preclinical development of drug 
leads (Simon et al., 2013). Using fluopol-ABPP, the first selective inhibitors of the serine 
hydrolases lysophospholipase 1 (LYPLA1) and lysophospholipase 2 (LYPLA2) were 
identified and found to act reversibly. For reversible inhibitors that lack known biomarkers 
such as endogenous substrates or products, demonstrating target engagement is challenging. 
To overcome this limitation, new ABPP probes were designed that reacted with serine 
hydrolases over an observable time window. In human cells and in mice, these moderately 
reactive ABPP probes could be used to accurately measure the target engagement and 
selectivity of the LYPLA1 and LYPA2 inhibitors. For instance, dosing mice with the 
inhibitors blocked more than 90% of LYPLA1 and LYPA2 activity in lung, heart and kidney 
tissue, whereas the activity of the enzymes was only reduced by about 50% in the brain and 
no detectable enzyme inhibition was seen in the liver (Adibekian et al., 2012).
More generally, fluopol-ABPP has proven useful for enzyme classes beyond serine 
hydrolases and has been used for screening glutathione S-transferases (Tsuboi et al., 2011), 
arginine methyltransferases (Dillon et al., 2012) and protein arginine deiminases (Knuckley 
et al., 2010).
Toward novel mechanisms of action compounds through multiplexed bioactivity data
Identifying small-molecule probes that modulate challenging targets often requires accessing 
new chemical starting points. Previous efforts to address this gap have typically focused on 
increasing diversity from a chemical structure perspective, a metric known to predict 
imperfectly the identity of compounds with new bioactivities. The MLP worked to develop 
high-throughput and inexpensive methods that would enable multiplexed cellular bioactivity 
measurements to guide directly the building of compound collections whose members have 
novel mechanisms of action.
Gene-expression studies have demonstrated the impact of unbiased, high-dimensional 
profiling data in defining disease states and also in inferring compound mechanism of action 
(Hughes et al., 2000; Lamb et al., 2006; Weinstein et al., 1997). High-content imaging could 
provide a complementary measurement for capturing complex disease phenotypes in 
unbiased, high-throughput formats. However, current high-content screening assays have 
either focused on a specific cellular process of interest or a limited set of cellular readouts, 
often based on labeled proteins or qPCR of target transcripts, or have been limited in 
throughput (Loo et al., 2007; Weinstein et al., 1997; Young et al., 2008). The MLP 
therefore focused on a ‘cell-painting assay’ that enables a more unbiased approach for 
characterizing alterations induced by disease states or small-molecule perturbagens 
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(Gustafsdottir et al., 2013). Using six dyes measured across five channels, 824 distinct 
cellular morphological features could be quantitatively imaged. In a pilot assay, small 
molecules known to have similar bioactivities were accurately clustered together based on 
similarities between image-based profiles. As cell morphology is impacted by many factors 
ranging from genetic and epigenetic to metabolic and environmental, we anticipate that the 
low cost, but high-dimensional imaging assay will facilitate identification of unexpected 
cellular alterations associated with small-molecule perturbations and disease.
While methods such as gene-expression profiling and the new image-based profiling assay 
contain rich information describing biological responses to small molecules, few approaches 
are available to use these data to understand structure–activity relationships (SAR). To 
enable more effective multi-parameter optimization of probes and therapeutic leads, the 
MLP developed a computational method to generate SAR information automatically from 
high-dimensional small-molecule profiling data (Wawer et al., 2014a). \Gene expression 
profiling data and cell-painting data were collected for about 20,000 DOS molecules and 
just over 2000 bioactive compounds. Association-rule mining was then used to define ‘rules’ 
of varying strengths that connected chemical attributes (e.g., contiguous substructures within 
compounds, shared synthetic histories) to biological effect patterns in the gene expression 
and imaging data. In one application of the methodology, identification of a DOS-based 
molecule that co-clustered with structurally unrelated microtubule destabilizers provided an 
opportunity for ‘scaffold hopping’ based on the signatures derived from this high-content 
information.
Rooted in these methodological advances, the question became whether multiplexed cellular 
small-molecule activity data could be used to create a screening library with maximal 
bioactivity (performance) diversity. There is general consensus that a small-molecule library 
that perturbs as many biological targets and induces as many distinct cellular phenotypes as 
possible would be most effective for cell-based screening. However, the data needed to 
create a priori such a screening collection were not previously available. As a consequence, 
assembling diverse screening collections has thus far focused primarily on the computed 
diversity of chemical structures. In one notable recent paper, a retrospective analysis of 
high-throughput screening data was used to assemble a library on the basis of biological 
activity (Petrone et al., 2012); however, this method, which is based on analysis of historical 
data, is not extensible to new candidate library members. The MLP measured gene-
expression and image-based profiles for over 12,000 bioactive compounds and over 17,000 
diversity-oriented synthesis (DOS)-based molecules for which HTS results from up to 178 
cell-based screens were available (Wawer et al., 2014b). We asked if the profiling data 
could select for compounds with diverse bioactivities, as judged by comparing patterns of 
activity in cells or against target proteins. Compounds selected based on varied activity in 
the imaging and gene expression assay profiles significantly outperformed compounds 
selected randomly or based on chemical diversity when their performance diversity in 
historical HTS assays was compared. In addition, we discovered thousands of compounds, 
many of which formed scaffold-based clusters, that induced cell morphology and gene 
expression patterns not seen within the 12,000 bioactives, likely hinting at novel 
mechanisms of action. These methods and others that yield multiplexed data reporting 
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complementary measures of compound activity offer a powerful route for prioritizing the 
synthesis and testing of small molecules more likely to modulate novel therapeutic targets.
New antiinfectives through chemical diversity
Many neglected infectious diseases are endemic to developing nations and the 
socioeconomic impact of these diseases is devastating. The impact of drug resistance and the 
lack of effective drugs are well exemplified by malaria and Chagas disease, respectively. In 
the case of malaria, there are several drugs available for treatment, but rapid emergence of 
resistant parasites poses a serious problem (Fidock, 2013). The currently available treatment 
options for Chagas disease are very limited and are efficacious only during the acute phase 
of the disease, not the chronic phase. Moreover, the severe adverse effects of the current 
anti-Chagas drugs lead to poor patient compliance (Bern, 2011). The development of safe 
new drugs for treating malaria and Chagas and other infectious diseases is urgently needed.
Identifying antimalarials and anti-trypanosomal agents with novel chemical structures and 
mechanisms of action may facilitate the development of therapies that are effective against 
parasites resistant to current drugs. DOS pathways have proven highly effective at rapidly 
generating novel, stereochemically rich compounds, including ones containing 8- to 14-
membered rings (Gerard et al., 2011; Lowe et al., 2012; Marcaurelle et al., 2010) and the 
MLP screening library contained more than 5,000 DOS compounds in this vein. These 
compounds, in conjunction with certain MLP probe-discovery projects that used a larger 
collection of 100,000 DOS compounds, have enabled the identification of small-molecule 
probes that act against these infectious agents through new mechanisms.
A cell-based malaria viability screen using an 8,000 DOS compounds led to the 
identification of a highly active hit with four stereogenic elements. Of the 15 other possible 
stereoisomers of the molecule that were present in the screening collection, only one had any 
detectable activity. Subsequent optimization, guided by these stereochemical insights, led to 
the identification of ML238 (Fig. 3), which is potent against both the chloroquine-resistant 
Dd2 strain (IC50 = 0.4 nM) and the wild-type 3d7 strain (IC50 = 0.6 nM) of Plasmodium 
falciparum (Heidebrecht et al., 2012; Weiwer et al., 2010). In addition, ML238 has good 
water solubility and does not lyse red blood cells (EC50 > 40,000 nM), which is important 
because it suggests a lack of broad cytotoxicity. To determine the compound’s mechanism 
of action, MLP generated ML238-resistant parasites and conducted whole-genome 
sequencing. These studies revealed that ML238 acts at the quinone reductase site of the bc1 
complex (Q1) (Lukens et al., 2014), which is on the opposite side of the cell membrane from 
the quinol oxidase site targeted by the antimalarial drug atovaquone. ML238 and atovaquone 
lacked cross-resistance and were synergistic in combination, highlighting the quinone 
reductase site as a antimalarial therapeutic target that may overcome atovaquone resistance 
(Lukens et al., 2014).
Similarly, a cell-based screen for molecules with selective lethality against Trypanosoma 
cruzi, the etiological agent of Chagas disease, identified ML341 (Fig. 3), a DOS-derived 
smallmolecule probe (Carmody et al., 2010; Dandapani et al., 2014). ML341 is potent 
against several strains of T. cruzi including the clinical cardiotropic isolate CA-1 strain, 
clone 72 (CA-I/72) (IC50 = 1 nM). Next, ML341 was evaluated for in vitro cidal activity 
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against a CA-I/72 strain in bovine skeletal muscle (BESM) cells. Emergence of the 
trypomastigote form of T. cruzi was monitored daily in infected BESM cells treated with 
ML341 or benznidazole, the current first line drug. In this stringent assay, ML341 was cidal 
at 40 nM, whereas benznidazole was cidal only at 6.6 uM.
In addition to this potency, ML341 was stable to mouse liver microsomes, which will 
facilitate the use of this probe in in vivo studies. Out of the 8 possible stereoisomers of 
ML341, only 2 stereoisomers were stable to mouse liver microsomes, a finding that helped 
guide further medicinal chemistry optimization. As seen in these two examples, having a 
comprehensive set of stereoisomers in the screening collection was crucial for evaluating 
rapidly stereochemistry-based SAR for potency and ancillary pharmacology.
Sphingosine-1-phosphate receptor modulators
Characterizing the mechanisms of action behind the anti-inflammatory properties of 
FTY720, a derivative of the fungal metabolite-derived serine palmityoltransferase inhibitor 
myriocin (Chen et al., 1999), led to the discovery that FTY720 modulates sphingosine-1-
phosphate (S1P) receptors to regulate lymphocyte tracking (Mandala et al., 2002). This 
finding then paved the way for the subsequent clinical development of FTY720 
(fingolimod), a sphingosine analog that modulates four of the five human S1P receptors, for 
the treatment of multiple sclerosis (Rosen et al., 2008). S1P receptors are expressed 
predominantly in immune, neural, endothelial and smooth muscles cells, and are believed to 
play roles that include regulating immune cell trafficking, endothelial barrier integrity and 
blood pressure, suggesting the potential to modulate specific receptor subtypes to treat a 
variety of diseases (Rosen et al., 2013).
To better validate individual S1P receptors as therapeutic targets, the MLP set out to identify 
small-molecule probes that selectively agonized or antagonized each receptor. A selective 
S1P1 antagonist (ML056, Fig. 3) with in vivo activity was developed through rational 
synthesis and used to explore the impact of perturbing this receptor on lymphocyte 
movement and function, providing evidence that the therapeutic effects of FTY720 are 
primarily mediated through this receptor (Sanna et al., 2006). The concomitant reduction in 
lymphocytes by the antagonist, resulting in endothelial leakage and severe pulmonary 
edema, showed that agonist therapy was the only tolerable choice for autoimmune disease 
(Rosen et al., 2013).
The poor water solubility of ML056 imparted by a hydrophobic strong zwitterion could be 
overcome both in vitro and in vivo by formulation as the reversible carbonate adduct. This 
derivatization was essential for the maintenance of complete receptor occupancy of stable 
S1PR1, which enabled the first successful crystal structure of a lipid-sensing GPCR (Hanson 
et al., 2012). When combined with biochemical studies, the S1P1 structure also provided 
insights into a new agonist binding mode used by compounds that include the second-
generation S1P1 agonist ML007 (Fig. 3). This series, identified in an allosteric agonist 
primary screen, was determined in a secondary assay to be subject to non-competitive 
inhibition by ML056, an orthosteric agonist, occupying the same site as the receptor's 
endogenous ligand. These studies defined a binding pocket distinct from S1P that affords 
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greater receptor selectivity and potentially a better pharmacokinetic profile and therapeutic 
index (Gonzalez-Cabrera et al., 2008).
Agonizing the S1P1 receptor to modulate immune cell trafficking may provide a therapeutic 
approach for diseases beyond multiple sclerosis. Clinical outcomes following influenza 
infection are determined by properties instrinsic to the virus strain and also differences in the 
host immune response. In particular, high cytokine levels and immune cell recruitment 
correlate with a poor outcome. In mice infected with a 2009 H1N1 pandemic influenza viral 
isolate, CYM-5442, an optimized derivative of ML007 with in vivo activity, inhibited the 
secretion of cytokines, reduced immune cell infiltration into the lung, and improved survival 
– while having no impact on viral titers (Teijaro et al., 2011; Walsh et al., 2011).
The MLP has also identified agonists of the S1P2 (ML031; Fig. 3) (Satsu et al., 2013), S1P3 
(ML249; Fig. 3) (Guerrero et al., 2010a; Jo et al., 2012; Urbano et al., 2013) and S1P4 
(ML248; Fig. 3) (Guerrero et al., 2010b; Guerrero et al., 2012) receptors, as well as an S1P4 
receptor antagonist (ML131; Fig. 3) (Guerrero et al., 2011; Oldstone et al., 2010; Urbano et 
al., 2011a; Urbano et al., 2011b), providing multiple first-in-class small-molecule probes for 
further eludidating the functions of this class of GPCRs. ML249, an allosteric agonist for the 
S1P receptor has been used to define orthosteric, allosteric and biopic space within the S1P3 
receptor binding pocket (Jo et al. 2012).
Antagonists of PPARγ phosphorylation
The thiazolidinedione (TZD) class of antidiabetic drugs comprises PPARγ agonists that 
increase expression of the insulin-sensitizing hormone adiponectin and decrease expression 
of insulin resistance-inducing hormones – in part contributing to their potent insulin-
sensitizing efficacy (Yu et al., 2002). Although drugs in this class are marketed to treat 
type-2 diabetes, their clinical utility has been limited by serious side effects seen in a 
minority of patients, including fluid retention (Staels, 2005), congestive heart failure (Nesto 
et al., 2003), and decreased bone density (Aubert et al., 2010).
The antidiabetic efficacy of these drugs was long thought to result from receptor agonism. 
Strikingly though, as additional PPARγ modulators were developed, drug efficacy correlated 
more tightly with ligand binding affinity than with agonist activity, prompting a closer 
examination of the mechanism through which PPARγ ligands improve insulin sensitization. 
PPARγ ligands that were potent insulin sensitizers were found to be highly effective at 
reducing obesity-induced phosphorylation of PPARγ at S273 in mice, despite varying levels 
of receptor agonism. Also, the therapeutic efficacy of the TZD rosiglitazone correlated with 
how effectively the drug reduced PPARγ phosphorylation at S273 in individual patients. 
Expression profiling in adipocytes revealed that phosphorylation of PPARγ at S273 leads to 
repression of a subset of target genes associated with obesity and insulin sensitivity (Choi et 
al., 2010). Recent studies have further shown that docking of the transcriptional repressor 
Thrap3 to phospho-S273 on PPARγ regulates the expression of diabetes-associated genes 
(Choi et al., 2014). Collectively these results suggest that blocking phosphorylation of 
PPARγ at S273, by normalizing expression of insulin sensitizing genes, is the dominant 
therapeutic mechanism of this drug class. However, it was not clear if small molecules could 
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be identified that sufficiently separated the two activities of TZDs and, if found, what the 
efficacy and safety profile of such compounds would be.
Starting from known potent partial agonists of PPARγ, the MLP synthesized and tested 
analogs to look for molecules that bind the receptor tightly and inhibit phosphorylation of 
S273, but are devoid of receptor agonist activity. Identifying small molecules that block a 
post-translational modification of a receptor is a challenging objective that was aided by a 
toolbox of methods developed by the MLP for characterizing nuclear receptor structure-
function (Marciano et al., 2014a). These efforts led to the non-agonist (antagonist) probe 
ML244 (SR1664; Fig. 3) (Choi et al., 2011; Kamenecka et al., 2010). Hydrogen-deuterium 
exchange (HDX), which has proven particularly effective for characterizing ligand-induced 
conformational dynamics of nuclear receptors (Marciano et al., 2014b), revealed that 
ML244 directly binds PPARγ, does not stabilize the Af2 surface of the receptor that is 
known to drive classical agonism, yet perturbs the surface of the ligand binding domain to 
induce a conformation that is not susceptible to phosphorylation of S273. Importantly, 
because ML244 binds PPARγ rather than directly inhibiting Cdk5, a kinase that mediates 
S273 phosphorylation of PPARγ, or any other kinase, the probe does not interfere with 
phosphorylation of other substrates in the proteome.
In mice fed a high-fat diet, ML244 reduced Cdk5-mediated phosphorylation of S273 on 
PPARγ, normalized serum glucose levels, and improved insulin sensitivity. In the leptin-
deficient ob/ob mouse model of severe obesity, ML244 reduced S273 PPARγ 
phosphorylation and improved glucose tolerance as effectively as rosiglitazone. However 
unlike rosiglitazone, ML244 did not cause weight gain or fluid retention in these mice or 
reduce bone-cell mineralization in culture. Ongoing efforts are now focusing on increasing 
the drug-like properties of the ML244 scaffold and testing the impact of the resulting 
compounds following once-a-day oral administration in obese mice.
Allosteric modulators of muscarinic receptors
About 30% of currently marketed drugs modulate GPCRs. The vast majority of GPCR-
targeted therapeutics act at an orthosteric site, These direct-acting ligands can have a number 
of potential drawbacks, including inducing toxicity and receptor desensitization or 
internalization. In addition, identifying selective orthosteric ligands has often been difficult 
(Conn et al., 2009a). Muscarinic acetylcholine receptors (mAChRs) have attracted 
significant interest as therapeutic targets in multiple neurological disorders. In Phase-II and 
Phase-III clinical trials, pan-orthosteric agonists of the five human mAchRs led to cognitive 
improvements and had anti-psychotic effects in Alzheimer's disease (AD) and 
schizophrenia. However, adverse events, which were believed to result from activation of 
the M2 mAChR and M3 mAChR in the periphery, prevented further clinical development of 
the compounds. Despite significant effort, selectively targeting the acetylcholine binding site 
of the mAchRs did not prove possible (Conn et al., 2009b) due to the high evolutionary 
conservation across subtypes for the endogenous acetylcholine ligand.
In contrast, allosteric sites are less evolutionarily conserved across receptor subtypes and 
have afforded exciting opportunities to achieve true subtype selectivity, as well as diverse 
pharmacology by stabilizing unique, activated conformations of the receptors. Moreover, 
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allosteric sites are generally lipophilic pockets, which could targeted by unique small-
molecule chemotypes that are structurally distinct from endogenous ligands (Conn et al., 
2009b; Wenthur et al., 2014). With this in mind, the MLP undertook screening efforts to 
identify selective positive allosteric modulators (PAMs) of mAChRs that could be used to 
dissect the individual contributions of these receptors to the therapeutic efficacy of pan-
mAChR agonists. These efforts were aided by employing functional assays that enabled the 
identification of PAMs and negative allosteric modulators (NAMs) in a single kinetic 
calcium assay. While the HTS afforded hits, these compounds did not have the 
physiochemical properties and CNS penetration needed for in vivo target validation 
experiments. Achieving high-quality small-molecule probes required significant medicinal 
chemistry optimization of the initial screening hits, leading to the identification of an M1-
selective PAM (ML169; Fig. 3) (Bridges et al., 2010; Reid et al., 2011; Tarr et al., 2012), an 
M4-selective PAM (ML253; Fig. 3) (Le et al., 2013; Niswender et al., 2010) and an M5-
selective PAM (ML326; Fig. 3) (Gentry et al., 2010; Gentry et al., 2013). All of these 
probes had submicromolar EC50s, at least ten-fold selectivity over the other receptor 
subtypes and, importantly, were brain penetrant.
In a mouse model of AD, the M1-selective probe ML169 potentiated chemically-induced 
excitation in the striatum, which is believed to mediate anti-psychotic effects, and favored 
the production of soluble, rather than amyloid, APP (Tarr et al., 2012). In a mouse model of 
schizophrenia, M4-selective ML253 reversed amphetamine-induced hyperlocomotion, 
recapitulating the effects of known anti-psychotic agents (Le et al., 2013). Further 
experiments are now focusing on using these probes to explore the biology and potential 
therapeutic relevance of these receptors, including investigating the role of M5, about which 
little is currently known.
Small-molecule activators of a metabolic enzyme
Tumor growth is associated with metabolic adaptations that facilitate cell-autonomous 
nutrient uptake, an increased rate of aerobic glycolysis, and a shift towards more anabolic 
metabolism to support cancer cell growth and proliferation. Emerging mechanistic insights 
into how metabolic pathways are regulated in cancer are pointing towards potential new 
therapeutic targets; however, which targets represent true cancer dependencies versus nodes 
where metabolic plasticity will allow cancer cells to adapt and to escape metabolism-
targeting therapeutics remains an open question. Small-molecule probes are urgently needed 
to study how metabolism is altered to support tumor growth and to identify cancer 
metabolism targets that could be exploited therapeutically.
Cancer cells in general adopt a less differentiated cell state and, analogous to less 
differentiated non-cancerous cells (e.g., adult stem cells), tend to rely on aerobic glycolysis. 
Pyruvate kinase, which catalyzes the final step in glycolysis, is derived from two gene 
products that each possesses two alternate splice isoforms. Cancer cells often express the 
M2 isozyme of pyruvate kinase (PKM2), which promotes aerobic glycolysis. In contrast, the 
M1 isozyme (PKM1) promotes glucose oxidation and is expressed in tissues with high ATP 
requirements such as muscle, heart and brain. The level of regulation of these isozymes is 
highly divergent. PKM1 has high constitutive activity, whereas PKM2 can adopt an active 
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or inactive conformation in response to signaling inputs. PKM1 expression increases 
oxidative glucose metabolism and can suppress both cell proliferation and tumor growth 
(Christofk et al., 2008; Israelsen et al., 2013; Lunt et al., 2015). However, the extent to 
which ectopic PKM1 expression recapitulates smallmolecule activation of PKM2 was 
unknown, leaving uncertain whether small-molecule modulation of PKM2 activity would 
lead to changes in tumor growth or viability.
More rigorously testing the potential of this therapeutic approach and better understanding 
the role of pyruvate kinase activity in cancer biology required small-molecule activators of 
PKM2, yet activating protein function is considered a tall order for small molecules. To 
address this gap, the MLP conducted a screen to identify molecules that increased PKM2 
activity in a biochemical assay. Three different chemotypes were identified and confirmed to 
be bona fide activators of PKM2. Subsequent optimization of these hits resulted in the 
identification of ML203 (DASA-58; Fig. 3) and ML265 (TEPP-46; Fig. 3), the first two 
reported PKM2 activators (Boxer et al., 2010). Further characterization demonstrated that 
the probes increase activity by stabilizing formation of the PKM2 tetramer, the more active 
form of the enzyme. This tetramer stabilization is further enhanced in the presence of 
fructose-1,6-bisphosphate (FBP), an endogenous activator of PKM2. Structural studies 
revealed that the synthetic small-molecule activators occupy a binding site at a monomer-
monomer interface distinct from the allosteric site bound by FBP (Anastasiou et al., 2012). 
Thus, these MLP probes enhance enzyme activity by stabilizing a protein-protein interaction 
– a mechanism of action generally viewed as challenging to accomplish (Thiel et al., 2012).
Next, the probes were used to explore the cancer contexts in which activating PKM2 might 
provide a therapeutic benefit. In cancer cell lines grown in culture, ML203 and ML265 
reduced cellular proliferation and had an impact on metabolite levels distinct from the 
changes observed with ectopic PKM2 expression (Anastasiou et al., 2012). A change in 
serine metabolism was among the most dramatic changes observed, and PKM2 activation 
can synergize with serine deprivation to slow the growth of cancer cells (Kung et al., 2012). 
Pyruvate kinase activation can also impair the growth of xenograft tumors with oral dosing 
of ML265 causing increased tumor latency and reduced tumor size (Anastasiou et al., 2012). 
Although these results provide initial evidence that activating PKM2 is tumor suppressive, 
the effect was relatively modest and the molecules had the highest efficacy in slowing tumor 
initiation.
A critical next step will be determining if there are established tumor contexts that are 
particularly dependent on low PK activity or if there are combination treatments that confer 
particular sensitivity to PKM2 activation, for instance modulators of serine metabolism. 
Beyond its role in tumors, regulated PK activity is also found in non-cancerous tissues, 
including the liver and red blood cells. Thus, activation of PKM2 or another PK isoform 
using small molecules could be beneficial in both cancer and non-cancer disease states. To 
this end, PK activators are currently being explored as therapeutics for pyruvate kinase 
deficiency, an inborn error of metabolism that specifically affects the red blood cell isoform 
of PK (Zanella et al., 2007).
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Stabilizing a folded lysosomal enzyme while retaining its activity
Gaucher's disease is a rare, autosomal disorder that results from a deficiency in the 
lysosomal enzyme glucocerebrosidase (GCase). Currently approved treatments for the 
disease include enzyme-replacement therapy, which is effective for some patients who have 
the most common form of the disease; however it is also expensive (Ortolano et al., 2014). 
When enzyme-replacement therapy is not an option, patients may be treated with a small 
molecule inhibitor of glucosylceramide synthetase, decreasing production of 
glucocerebrosides, the substrate of GCase that accumulates in disease. This therapy is 
associated with a number of side effects including weight loss, tremors and peripheral nerve 
damage (Larsen et al., 2012). Neither of these treatments is effective against neuropathic 
forms of the disease (Suzuki, 2013).
Many GCase mutants found in Gaucher’s patients are enzymatically active, but are 
improperly folded by endoplasmic reticulum (ER) chaperone proteins, causing ER 
accumulation and degradation before the protein reaches the lysosome (Orvisky et al., 
2002). As a result, current drug-discovery efforts are focusing on identifying chemical 
chaperones that bind mutant GCase to increase the fraction of properly folded enzyme and 
promote greater trafficking to the lysosome. Chemical chaperones identified to date are 
transition-state mimetics that stabilize the enzyme, but also inhibit enzymatic activity 
(Suzuki, 2013). The most advanced chemical GCase chaperone, isofagomine, was recently 
tested in Phase-II clinical trials. Isofagomine increased GCase levels in the white blood cells 
of all patients treated, demonstrating its capacity to increase trafficking. However, the 
treatment only led to a clinical improvement in one of 18 patients who completed the study, 
probably due to isofagomine’s inhibition of GCase activity (Panicker et al., 2012).
Chemical chaperones that stabilize the enzyme without inhibiting activity may provide a 
therapeutic approach with improved efficacy. To identify such compounds, the MLP 
developed a high throughput dose response assay that used a spleen homogenate solution 
from a patient with Gaucher’s disease, thus creating an assay using mutant enzyme in a 
physiological environment. This assay enabled the identification of a pyrazolopyrimidine-
based molecule that was optimized to the small-molecule probe ML198 (Fig. 3) (Goldin et 
al., 2012; Rogers et al., 2010). In three patient-derived dermal fibroblast lines with distinct 
genotypes, ML198 increased the activity and lysosomal localization of mutant GCase. 
Moreover, in macrophages from Gaucher's patients, ML198 reduced aberrant lipid 
accumulation and normalized phagocytic and efferocytosis function. The MLP probe also 
displayed good pharmacokinetics and brain penetration in mice (Patnaik et al., 2012).
Innovating small-molecule discovery
Human biology is providing new insights into therapeutic targets. For example, human 
genetics is revealing risk and protective variants of genes across a range of diseases. 
Biochemical investigations of variant proteins can provide a blueprint or recipe to follow 
that defines the activity that a drug should confer on the more common version of the 
protein. However, the activities suggested by these 'experiments of nature’ (Plenge et al., 
2013) are challenging and generally unfamiliar to historical drug discovery. For example, 
rather than pointing to the need for inhibiting a specific protein kinase, they might highlight 
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the need for stabilizing a specific protein such as APP or ApoE to reduce levels of a post-
translational modification (Jonsson et al., 2012; Mahley and Huang, 2012). Drugs don’t yet 
exist that have these mechanisms of action. To realize the promise of precision medicine 
there is a great need to innovate chemistry, chemical biology and other areas of science and 
engineering related to therapeutics discovery if we are to uncover the kinds of mechanism of 
action compounds suggested by human biology.
The MLP has been an early pioneer in efforts to develop small-molecule probes with novel 
mechanisms of action. One of the lessons learned was the power of close collaborations of 
academic biologists and clinicians with chemists and chemical biologists for developing 
effective and informative probes that facilitate studies of emerging biology. Another insight 
gained was the critical importance of devoting sufficient resources to chemical optimization. 
Hits straight from screens rarely have the potency and selectivity necessary to be effective 
tool compounds – and if used with insufficient caution can lead to non-robust conclusions 
(Begley and Ellis, 2012). Some percentage of hits identified in screens are likely 
promiscuous compounds unlikely to ever yield tool compounds (Baell and Walters, 2014). 
Other hits are good starting points, but require a substantial investment in “hit-to-probe” 
chemistry. When this investment is made, the resulting compounds can provide unique 
avenues for exploring biology. For instance, the MLP has discovered many small-molecule 
probes that modulate targets via mechanisms that are difficult or impossible to explore by 
genetic perturbations, such as altering the rate of protein modifications (noted above), 
disrupting protein–protein interactions, increasing protein stability and inhibiting protein 
dimerization (Supplementary Table 1).
The MLP has not been alone in recognizing the critical experimental niche filled by small-
molecule probes (Edwards et al., 2015; Edwards et al., 2011; Frye, 2010; Workman and 
Collins, 2010). Numerous academic and industrial efforts, including public–private 
partnerships such as the one led by the Structural Genomics Consortium, now focus on 
identifying and publishing potent and selective small molecules. As a result, the use of 
small-molecule probes has become a more established part of the biologist’s toolkit.
Once high-quality small-molecule probes are developed, one of the biggest current hurdles 
to translation is that preclinical models do not accurately predict efficacy and toxicity in 
humans. Academically initiated human experiments, for example, involving Phase-0 (the 
FDA exploratory IND path) or Phase-I trials – if performed with safe compounds – could be 
used to look for target engagement and the modulation of biomarkers likely to be predictive 
of efficacy. Testing disease hypotheses emerging from human biology with on-mechanism 
small molecules in humans, although insufficient for drug approval, would almost certainly 
increase the probability of successful drug development and eventual approval.
In addition to enabling advances in biological understanding, small-molecule probes are 
more directly impacting therapeutic discovery. For instance, in multiple cases, 
biotechnology or pharmaceutical companies have licensed the intellectual property around 
MLP probes (Table 1). This investment speaks to the potential for academic small molecule 
probe discovery to impact drug discovery efforts. However, there remains an alarming 
Schreiber et al. Page 15
Cell. Author manuscript; available in PMC 2016 June 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
disconnect between the pace at which potential therapeutic targets are uncovered and our 
ability to develop small molecules with the desired activity.
In contrast to a decade ago, the infrastructure and expertise for small molecule discovery is 
firmly rooted in academic settings. Innovative small molecule science is now embedded in 
academia alongside deep and rapidly advancing biomedical knowledge (Reed et al., 2012). 
Advancing small-molecule discovery in this environment, particularly when methods, data 
and small-molecule probes are made openly available, may provide an effective bridge 
towards more rapidly identifying small molecules that modulate the challenging 
mechanisms illuminated by human biology to accelerate the testing of emerging therapeutic 
hypotheses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Centers comprising the MLPCN Network
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Fig. 2. Spectrum of targets modulated by MLP probes
Target classes modulated by MLP probes are visualized based on HTS data and user-defined 
thresholds. Arc lengths represent the number of distinct targets within a target class that are 
modulated by this collection of probes. This graph was generated using the BioAssay 
Research Database (BARD; bard.nih.gov), which was generated by the MLP to enable users 
to mine and visualize small-molecule activity data. The graph depicts the bioactivity of 
about 65% of the total number of MLP probes across 415 unique assays associated with 460 
targets, which were categorized using the Panther database into 110 protein categories. The 
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breadth of target classes highlights the diverse biology and target space explored by the 
MLP.
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Fig. 3. MLP probes highlighted in vignettes
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Table 1
Translational trajectory for MLP probes.
Targets MLP probes Post-MLP trajectory
Serine hydrolases ML081, ML174, 
ML211, ML225, 
ML226, ML256, 
ML257, ML294, 
ML295, ML296
Screening and assay platforms, serine hydrolase-directed small-molecule libraries and serine 
hydrolase inhibitors, resulting in part from MLP projects, have been licensed to Abide 
Therapeutics, which is pursuing the further identification, preclinical, and clinical 
development of serine hydrolase inhibitors for a variety of indications, in particular 
neurological, immunological and metabolic diseases.
P. falciparum, T. 
cruzi
ML238, ML341 The identification of the MLP malaria probe led to a Gates Foundation-funded Chemical 
Diversity Initiative that has explored the use of the DOS collections more broadly in infectious 
disease and has yielded promising compounds that target the etiological agents of malaria 
tuberculosis via novel mechanisms. In work supported by the Global Health Innovation 
Technology (GHIT) fund and in collaboration with Eisai, the MLP anti-trypanosomal probe is 
being optimized to enable in vivo proof of concept studies and a DOS-based antimalarial agent 
is being optimized towards IND-enabling studies.
S1P1 agonists ML007 Receptos licensed intellectual property surrounding S1P1 agonists including the racemate of 
its clinical candidate RPC1063, which is currently in two Phase- III studies in relapsing 
multiple sclerosis and about to enter Phase-III testing in ulcerative colitis and Phase-II testing 
in Crohn’s disease.
M4 mAChR ML108, ML253 AstraZeneca has licensed intellectual property associated with the M4 PAMs and the company 
is pursuing preclinical development of the compounds as a potential treatment for the 
neuropsychiatric symptoms associated with AD and schizophrenia.
GCase ML198 This probe and related analogs have been licensed to Lysosomal Therapeutics Inc., which is 
pursuing preclinical development of these non-inhibitory GCase chaperones.
Integrin αIIbβ3 
receptor antagonist
ML165 Rockefeller Medical School and NCATS are pursuing an IND based on a derivative of ML165 
indicated for pre-hospital therapy of patients with ST segment elevated myocardial infarction 
(STEMI).
P97 AAA ATPase 
inhibitor
ML240 Cleave BioSciences licensed intellectual property surrounding ML240. A derivative of this 
probe, CB-5083, is currently in two Phase-I studies, one in relapsed and refractory multiple 
myeloma and the other in solid tumors refractory to the standard-of-care.
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